Clinical trial
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV…
NCT00257465 · AVAX Technologies, Industry · Completed
Key facts
| NCT number | NCT00257465 |
|---|---|
| Title | Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma |
| Official title | M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma |
| Lead sponsor | AVAX Technologies, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | Autologous, DNP-modified vaccine (M-Vax), DNP-Modified Melanoma Vaccine, DNP-Modified Vaccine |
| Enrollment | 82 |
| Start date | Jun 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 23, 2005 |
| Last update posted | Dec 3, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: